Open an account

Canopy Growth

CGC · TORONTO

$0.6758+$0.0105 (+1.58%)TodayMarket closed ·
Prev close $0.6653

About CGC

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The firm brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

Employees
960
Headquarters
Smiths Falls, Ontario
Listed
Jun 4, 2010
Sector
Health Care
Industry
Pharmaceuticals
Website
canopygrowth.com

CGC key statistics

Market cap
397.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.63M
Volume
1.88M
Open price
$0.675
High today
$0.6785
Low today
$0.65
52 Week high
$2.38
52 Week low
$0.654

Canopy Growth (CGC) at a glance

Canopy Growth (CGC) last traded at $0.6758, with a market cap of 397.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.65 and $0.6785. The current price is 4.0% above the day's low and 0.4% below its high.

Volume so far is 1.88M shares, below the average of 2.63M shares a day.

Over the past year Canopy Growth has ranged from $0.654 to $2.38, and now sits 1% of the way up that range.

Canopy Growth met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY27 it reported -$0.03 per share against an estimate of -$0.1156.

The average analyst price target is $1.68, 148.2% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 6 analystsAvg $1.68
Low
$1.01
Now
$0.6758
High
$3.75

CGC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 58.7% on average.

  1. Q2 FY25: reported -$1.48 per share against an estimate of -$0.447
  2. Q3 FY25: reported -$1.11 per share against an estimate of -$0.5518
  3. Q4 FY25: reported -$1.47 per share against an estimate of -$0.4794
  4. Q1 FY26: reported -$0.22 per share against an estimate of -$0.2397
  5. Q2 FY26: reported -$0.01 per share against an estimate of -$0.1612
  6. Q3 FY26: reported -$0.18 per share against an estimate of -$0.0459
  7. Q4 FY26: reported -$0.404 per share against an estimate of -$0.0986
  8. Q1 FY27: reported -$0.03 per share against an estimate of -$0.1156

CGC news

  • Press releaseBusiness Wire

    Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026

  • Press releaseBusiness Wire

    Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower

  • Press releaseBusiness Wire

    Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany

  • Press releaseBusiness Wire

    Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum

  • Press releaseBusiness Wire

    Canopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special Meeting

  • Press releaseBusiness Wire

    Canopy Growth Expands European Medical Cannabis Supply Into the UK

  • Press releaseBusiness Wire

    Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline

  • Press releaseBusiness Wire

    Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

Similar companies

Companies in the same industry as Canopy Growth

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.